Epredia lance des imprimantes à cassettes laser conçues pour améliorer le suivi des échantillons et l'efficacité des laboratoires

Les imprimantes à cassettes laser sont conçues pour améliorer le suivi des échantillons et l'efficacité des laboratoires.

Portsmouth, NH
November 1, 2024

Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE 6523), announces its SlideMateTM Laser slide printer has received an Innovative Technology designation for improving laboratory efficiency and sample traceability from Vizient, Inc., the largest healthcare provider performance improvement company in the country. Epredia exhibited SlideMate Laser at the Vizient Innovative Technology Exchange Sept. 18 in Las Vegas.

Each year, healthcare experts serving on Vizient provider-led councils review select products and technologies for their potential to enhance clinical care, patient safety, or healthcare worker safety or to improve business operations of healthcare organizations. Innovative Technology designations are awarded to previously contracted products to signal to healthcare providers the impact of these innovations on patient care and the business models of healthcare organizations.
Epredia’s SlideMate portfolio of slide printers is used in the cancer diagnostics process to identify and help track tissue samples. The company designed SlideMate Laser for clinical laboratories of any size looking to improve sample traceability. SlideMate Laser provides high-resolution, 600-dpi laser printing on microscope slides, enabling laboratories to include more identifying information directly on the tab of the slides that pathologists use in the cancer diagnostics workflow. This technology can embed up to 50 characters in a barcode on each slide, compared to 23 characters with traditional thermal transfer and ink jet technologies, improving both patient sample tracking and efficiency. 

SlideMate Laser also enhances laboratory efficiency by optimizing the slide movements through the printer and reducing potential downtime compared to thermal transfer and ink jet printers. Without the need to purchase, ink, bulbs or tape for slide printers, users can expect lower operational costs. With both on-demand and batch printing options, SlideMate Laser can integrate into a range of workflows. The laser printer’s software is easy to use and can be directly interfaced to a Laboratory Information System.

SlideMate Laser is the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow. Epredia also offers the specialized slides designed for use with SlideMate Laser to help laboratories make a smooth transition to precision laser printing.

Steven Lynum, President of Epredia, said, “We set out to transform the anatomical pathology market with precision cancer diagnostics solutions. The Vizient Innovative Technology Designation is a true honor, and further proof that SlideMate Laser contributes to our goal of providing a seamless end-to-end laboratory workflow. Our team remains focused on improving patient outcomes by enabling pathologists to do their best work.”

“Congratulations to Epredia for achieving this peer-designated status,” said Kelly Flaharty, senior director contract services and Vizient Innovative Technology Program leader. “Our customer council deemed the SlideMate Laser worthy of this designation for its potential to make a real difference in the healthcare industry.”

Vizient represents a diverse customer base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and has a portfolio that represents more than $140 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle. 

---

A propos d'Epredia

Epredia est un leader mondial dans le domaine de l'anatomopathologie.

Epredia est un leader mondial dans le domaine de la pathologie anatomique, fournissant des solutions complètes pour le diagnostic de précision du cancer et le diagnostic des tissus. S'appuyant sur des marques clés telles que Erie Scientific, Menzel-Gläser, Microm, Shandon et Richard-Allan Scientific, le portefeuille d'Epredia comprend des lames de microscope, des instruments et des consommables. Epredia a été créée à la suite de l'acquisition de l'activité de pathologie anatomique de Thermo Fisher Scientific par PHC Holdings en 2019. Epredia est présente sur des sites importants aux États-Unis, au Royaume-Uni, en Allemagne, en Suisse et en Chine, avec un total d'environ 1 200 employés. Epredia s'engage à réaliser sa mission d'améliorer les vies en améliorant les diagnostics de cancer pour les patients du monde entier. Pour plus d'informations sur Epredia et ses produits, veuillez consulter www.epredia.com.

La société Epredia a pour mission d'améliorer les vies en améliorant les diagnostics du cancer pour les patients du monde entier.

A propos de PHC Holdings Corporation (Groupe PHC)

La société PHC Holdings Corporation (Groupe PHC)

PHC Holdings Corporation (TSE 6523) est une entreprise mondiale de soins de santé dont la mission est de contribuer à la santé de la société par le biais de solutions de soins de santé qui ont un impact positif et améliorent la vie des gens. Ses filiales (appelées collectivement PHC Group) comprennent PHC Corporation, Epredia, Ascensia Diabetes Care, LSI Medience Corporation, Mediford et Wemex. Ensemble, ces entreprises développent, fabriquent, vendent et entretiennent des solutions dans les domaines de la gestion du diabète, des solutions de soins de santé, des sciences de la vie et du diagnostic. Les ventes nettes consolidées de PHC Group’étaient de 356,4 milliards de yens pour l’exercice 2022, avec une distribution mondiale de produits et de services dans plus de 125 pays.
www.phchd.com

Pour plus d'informations, veuillez contacter :

Julia Cottran, directrice générale de l'entreprise.
Julia Cottrill
Communication d'entreprise du groupe HPC
Email : julia.cottrill@phchd.com

Julia Cottrill
GroupePHC Communications
Courriel